{"name":"Janssen-Cilag S.p.A.","slug":"janssen-cilag-s-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Darunavir/Ritonavir (DRV/r)","genericName":"Darunavir/Ritonavir (DRV/r)","slug":"darunavir-ritonavir-drv-r","indication":"HIV-1 infection in treatment-experienced patients","status":"phase_3"},{"name":"Efavirenz (EFV)","genericName":"Efavirenz (EFV)","slug":"efavirenz-efv","indication":"HIV-1 infection (in combination with other antiretroviral agents)","status":"marketed"}]}],"pipeline":[{"name":"Darunavir/Ritonavir (DRV/r)","genericName":"Darunavir/Ritonavir (DRV/r)","slug":"darunavir-ritonavir-drv-r","phase":"phase_3","mechanism":"Darunavir is a protease inhibitor that blocks HIV protease, preventing viral polyprotein cleavage and maturation, while ritonavir acts as a pharmacokinetic booster to increase darunavir levels.","indications":["HIV-1 infection in treatment-experienced patients","HIV-1 infection in treatment-naïve patients"],"catalyst":""},{"name":"Efavirenz (EFV)","genericName":"Efavirenz (EFV)","slug":"efavirenz-efv","phase":"marketed","mechanism":"Efavirenz inhibits HIV reverse transcriptase, blocking the enzyme that converts viral RNA into DNA and preventing HIV replication.","indications":["HIV-1 infection (in combination with other antiretroviral agents)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNbFk1Qjc4d1NTVzY4Y0RuR1U3R3gyTlB0bmlJQmtNc3BJQkhEbFZyWU5mVF9RaXFrRXFTNTE3N0lqcTY5bl9KZm9JVTdBY1AxUkdmNXYxbnBtQ3pOdkVKZXNtTWZ1Q0tlVmpTUnpWUXkydkZHSHVZSFFqcTNmM0xvWDNfbGprOXVQRmhfQ1dlZkNjLTFGLVpJUlRKeWpnbUJpSWRTTUJuQzB0ZUdWVXVCQlVPczZKdTg5ZE5RdnExaEpnZw?oc=5","date":"2020-07-21","type":"pipeline","source":"emjreviews.com","summary":"Advancing the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway - emjreviews.com","headline":"Advancing the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}